Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tregs activated by bispecific antibodies: Killers or suppressors?

Literature DB >> 25949920

Tregs activated by bispecific antibodies: Killers or suppressors?

Stefanie Koristka¹, Marc Cartellieri², Claudia Arndt¹, Anja Feldmann³, Barbara Seliger⁴, Gerhard Ehninger⁵, Michael P Bachmann⁶.

Abstract

In recent years, bispecific antibodies (bsAb) have emerged as promising tools for a target-specific redirection of T cells in order to eliminate malignant cells. However, CD3-engaging constructs might also activate T regulatory cells (Tregs) present in the tumor microenvironment. Whether this has detrimental or beneficial effects for tumor therapy is still controversially discussed.

Entities: Disease

Keywords: T cell retargeting; T regulatory cells; cytotoxicity; immunosuppression, immunotherapy; single-chain bispecific antibodies

Year: 2015 PMID： 25949920 PMCID： PMC4404924 DOI： 10.4161/2162402X.2014.994441

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

9 in total

1. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation.

Authors: Petra Hoffmann; Tina J Boeld; Ruediger Eder; Jochen Huehn; Stefan Floess; Georg Wieczorek; Sven Olek; Wolfgang Dietmaier; Reinhard Andreesen; Matthias Edinger
Journal: Eur J Immunol Date: 2009-04 Impact factor: 5.532

Review 2. Regulatory T cells in cancer immunotherapy.

Authors: Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal: Curr Opin Immunol Date: 2014-01-14 Impact factor: 7.486

3. Retargeting of human regulatory T cells by single-chain bispecific antibodies.

Authors: Stefanie Koristka; Marc Cartellieri; Anke Theil; Anja Feldmann; Claudia Arndt; Slava Stamova; Irene Michalk; Katrin Töpfer; Achim Temme; Karsten Kretschmer; Martin Bornhäuser; Gerhard Ehninger; Marc Schmitz; Michael Bachmann
Journal: J Immunol Date: 2011-12-19 Impact factor: 5.422

4. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells.

Authors: Anja Feldmann; Claudia Arndt; Katrin Töpfer; Slava Stamova; Franziska Krone; Marc Cartellieri; Stefanie Koristka; Irene Michalk; Dirk Lindemann; Marc Schmitz; Achim Temme; Martin Bornhäuser; Gerhard Ehninger; Michael Bachmann
Journal: J Immunol Date: 2012-08-08 Impact factor: 5.422

5. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats.

Authors: Anja Feldmann; Slava Stamova; Claudia C Bippes; Holger Bartsch; Rebekka Wehner; Marc Schmitz; Achim Temme; Marc Cartellieri; Michael Bachmann
Journal: Prostate Date: 2010-12-28 Impact factor: 4.104

6. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Authors: Bryan D Choi; Patrick C Gedeon; James E Herndon; Gary E Archer; Elizabeth A Reap; Luis Sanchez-Perez; Duane A Mitchell; Darell D Bigner; John H Sampson
Journal: Cancer Immunol Res Date: 2013-09 Impact factor: 11.151

7. Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway.

Authors: Olga V Efimova; Todd W Kelley
Journal: BMC Immunol Date: 2009-11-22 Impact factor: 3.615

8. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.

Authors: Bryan D Choi; Patrick C Gedeon; Luis Sanchez-Perez; Darell D Bigner; John H Sampson
Journal: Oncoimmunology Date: 2013-10-22 Impact factor: 8.110

9. Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity.

Authors: S Koristka; M Cartellieri; C Arndt; A Feldmann; K Töpfer; I Michalk; A Temme; G Ehninger; M Bachmann
Journal: Blood Cancer J Date: 2014-04-11 Impact factor: 11.037